scholarly journals Spectrum of Skeletal and Non-Skeletal Manifestations of Morquio A Syndrome in an Adult: A Case Report

Author(s):  
Sharma VP Sharma K Arvind
2019 ◽  
Vol 6 (2) ◽  
pp. 121-124
Author(s):  
Amina Benbellal ◽  
◽  
Hanène Belabbassi ◽  
Sarrah Ait Ziane ◽  
Houria Kaced

La maladie de Morquio A, ou mucopolysaccharidose de type IV A (Morquio A syndrome, MPS IVA), est une maladie génétique rare ; multisystémique, et extrêmement invalidante. Elle est liée à un déficit enzymatique en N-acétylgalactosamine-6-sulfate sulfatase (GALNS), enzyme lysosomale responsable de la dégradation du kératane sulfate (KS) et de la chondroïtine-6-sulfate (C6S), éléments présents principalement dans le cartilage et la cornée. Cette maladie métabolique se manifeste principalement par une atteinte osseuse constante, sous forme d’une dysplasie spondylo-épi-métaphysaire progressive, et des complications ophtalmologiques, auditives et cardiaques plus modérées d’apparition tardive. Nous relatons le cas d’un enfant âgé de 8 ans qui présente cette pathologie, en étayant ses caractéristiques cliniques, et ses modalités thérapeutiques pluridisciplinaires.


2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Andrea Gómez-González ◽  
Miguel Ángel Rosales-Berber ◽  
Paola De Ávila-Rojas ◽  
Amaury Pozos-Guillén ◽  
Arturo Garrocho-Rangel

Mucopolysaccharidosis type IV A or Morquio syndrome is an uncommon inherited metabolic condition caused by the deficient intralysosomal storage of glycosaminoglycans. Diagnosis is typically based on clinical examination, skeletal radiographs, and histochemical tests in blood cells or fibroblasts. It is characterized by evident skeletal deformities, poor joint mobility, severe growth deficit, occlusal anomalies, and enamel defects. The aim of the present clinical case report is to describe the general oral management provided to a 6-year-old female patient and its corresponding evolution for more than three years.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Sebile Kılavuz ◽  
Sibel Basaran ◽  
Deniz Kor ◽  
Fatma Derya Bulut ◽  
Sevcan Erdem ◽  
...  

Abstract Background This case series includes longitudinal clinical data of ten patients with Morquio A syndrome from south and southeastern parts of Turkey, which were retrospectively collected from medical records. All patients received enzyme replacement therapy (ERT). Clinical data collected included physical appearance, anthropometric data, neurological and psychological examinations, cardiovascular evaluation, pulmonary function tests, eye and ear-nose-throat examinations, endurance in the 6-min walk test and/or 3-min stair climb test, joint range of motion, and skeletal investigations (X-rays, bone mineral density). Results At the time of ERT initiation, two patients were infants (1.8 and 2.1 years), five were children (3.4–7.1 years), and three were adults (16.5–39.5 years). Patients had up to 4 years follow-up. Most patients had classical Morquio A, based on genotypic and phenotypic data. Endurance was considerably reduced in all patients, but remained relatively stable or increased over time in most cases after treatment initiation. Length/height fell below normal growth curves, except in the two infants who started ERT at ≤ 2.1 years of age. All patients had skeletal and/or joint abnormalities when ERT was started. Follow-up data did not suggest improvements in skeletal abnormalities, except in one of the younger infants. Nine patients had corneal clouding, which resolved after treatment initiation in the two infants, but not in the other patients. Hepatomegaly was reported in seven patients and resolved with treatment in five of them. Other frequent findings at treatment initiation were coarse facial features (N = 9), hearing loss (N = 6), and cardiac abnormalities (N = 6). Cardiac disease deteriorated over time in three patients, but did not progress in the others. Conclusions Overall, this case series with Morquio A patients confirms clinical trial data showing long-term stabilization of endurance after treatment initiation across ages and suggest that very early initiation of ERT optimizes growth outcomes.


2015 ◽  
Vol 3 ◽  
pp. 232640981557618 ◽  
Author(s):  
Christina Lampe ◽  
Mohit Jain ◽  
Andrew Olaye ◽  
Bianca Meesen ◽  
Celeste Decker ◽  
...  

2017 ◽  
Vol 381 ◽  
pp. 193 ◽  
Author(s):  
N.N. Ibáñez Castañeda ◽  
N.N. Castañeda Ibáñez ◽  
M.A. Mora Matallana ◽  
M.A. Prado Rivera ◽  
A. Rizo Arévalo ◽  
...  

2018 ◽  
Vol 176 (12) ◽  
pp. 2595-2603
Author(s):  
Giulia Facchina ◽  
Alessandro Amaddeo ◽  
Geneviève Baujat ◽  
Sylvain Breton ◽  
Caroline Michot ◽  
...  

1997 ◽  
Vol 10 (3) ◽  
pp. 223-232 ◽  
Author(s):  
Susanna Bunge ◽  
Wim J. Kleijer ◽  
Anna Tylki-Szymanska ◽  
Cordula Steglich ◽  
Michael Beck ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document